Pyxis Oncology, Inc. (PYXS)
After hours:
| Previous close | 3.2100 |
| Open | 3.2200 |
| Bid | 3.2500 x 200 |
| Ask | 3.3000 x 200 |
| Day's range | 3.1300 - 3.5000 |
| 52-week range | 1.3500 - 6.8500 |
| Volume | |
| Avg. volume | 601,104 |
| Market cap | 194.921M |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3700 |
| Earnings date | 11 Aug 2024 - 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.83 |
GlobeNewswirePyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hir
Simply Wall St.Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green
Key Insights Significantly high institutional ownership implies Pyxis Oncology's stock price is sensitive to their...
- GlobeNewswire
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Na
